Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

Major Depressive Disorder, Recurrent Clinical Trial

Official title:
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients With Major Depressive Disorder

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant monotherapy with one of identified selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or bupropion. The primary hypothesis of the study is that filorexant is superior to placebo as augmentation therapy with respect to change from baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total score.

Clinical Trial Description

Participants will continue to take their pretrial antidepressant medication as prescribed throughout the trial. Participants will be randomized in a 1:1 ratio to receive filorexant or placebo for a 6-week treatment period. Following completion of the treatment period, participants will enter a 2-week double-blind run-out period. During the run-out period, participants who received placebo in the 6-week treatment period will continue to receive placebo and participants who received filorexant in the 6-week treatment period will be randomized to receive either filorexant or placebo in a 1:1 ratio. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01554176
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Terminated
Phase	Phase 2
Start date	May 18, 2012
Completion date	September 3, 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03735576` - Cognitive Behavioural Therapy for the Treatment of Late Life Depression	N/A
Completed	`NCT03899168` - Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging	N/A
Recruiting	`NCT05913960` - Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway	N/A
Completed	`NCT01931995` - Investigation of Brain Network Dynamics in Depression	N/A
Completed	`NCT03353493` - Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder	N/A
Completed	`NCT04481737` - Peer-delivered and Technology-Assisted Integrated Illness Management and Recovery	N/A
Terminated	`NCT03254342` - MRS and Medication Response: A Pilot Study
Completed	`NCT02307617` - Glutamate Probes in Adolescent Depression